AAAAAA
Results:
1-16
|
Results: 16
Authors:
Zisman, A
Ng, CP
Pantuck, AJ
Bonavida, B
Belldegrun, AS
Citation: A. Zisman et al., Actinomycin D and gemcitabine synergistically sensitize androgen-independent prostate cancer cells to Apo2L/TRAIL-mediated apoptosis, J IMMUNOTH, 24(6), 2001, pp. 459-471
Authors:
Chao, D
Zisman, A
Freedland, SJ
Pantuck, AJ
Said, JW
Belldegrun, AS
Citation: D. Chao et al., Sarcomatoid renal cell carcinoma: basic biology, clinical behavior and response to therapy, UROL ONCOL, 6(6), 2001, pp. 231-238
Authors:
Wieder, J
Freedland, SJ
Pantuck, AJ
Zisman, A
Belldegrun, AS
Citation: J. Wieder et al., Update on gene and immune based therapy for urologic malignancy, UROL ONCOL, 6(6), 2001, pp. 265-275
Authors:
Zisman, A
Pantuck, AJ
Dorey, F
Said, JW
Shvarts, O
Quintana, D
Gitlitz, BJ
deKernion, JB
Figlin, RA
Belldegrun, AS
Citation: A. Zisman et al., Improved prognostication of renal cell carcinoma using an integrated staging system, J CL ONCOL, 19(6), 2001, pp. 1649-1657
Authors:
Zisman, A
Pantuck, AJ
Figlin, RA
Belldegrun, AS
Citation: A. Zisman et al., Validation of the UCLA integrated staging system for patients with renal cell carcinoma, J CL ONCOL, 19(17), 2001, pp. 3792-3793
Authors:
Pantuck, AJ
Belldegrun, AS
Figlin, RA
Citation: Aj. Pantuck et al., Nephrectomy and interleukin-2 for metastatic renal-cell carcinoma, N ENG J MED, 345(23), 2001, pp. 1711-1712
Authors:
Wieder, JA
Belldegrun, AS
Citation: Ja. Wieder et As. Belldegrun, The utility of PSA doubling time to monitor prostate cancer recurrence, MAYO CLIN P, 76(6), 2001, pp. 571-572
Authors:
Pantuck, AJ
Zisman, A
Belldegrun, AS
Citation: Aj. Pantuck et al., The changing natural history of renal cell carcinoma, J UROL, 166(5), 2001, pp. 1611-1623
Authors:
Zisman, A
Pantuck, AJ
Chao, D
Dorey, F
Said, JW
Gitlitz, BJ
de Kernion, JB
Figlin, RA
Belldegrun, AS
Citation: A. Zisman et al., Reevaluation of the 1997 TNM classification for renal cell carcinoma: T1 and T2 cutoff point at 4.5 rather than 7 cm. Better correlates with clinicaloutcome, J UROL, 166(1), 2001, pp. 54-58
Authors:
Freedland, SJ
Belldegrun, AS
Citation: Sj. Freedland et As. Belldegrun, Editorial: Towards kidney cancer crystal ball. Better prognostication of patients with renal cell carcinoma, J UROL, 166(1), 2001, pp. 73-74
Authors:
Pantuck, AJ
Zismon, A
Tso, CL
Belldegrun, AS
Citation: Aj. Pantuck et al., Intermittent androgen deprivation therapy: schedule modifications based ona novel in vivo human xenograft model, PROSTATE C, 3(4), 2000, pp. 280-282
Authors:
Pantuck, AJ
Zisman, A
Belldegrun, AS
Citation: Aj. Pantuck et al., Gene therapy for prostate cancer at the University of California, Los Angeles: preliminary results and future directions, WORLD J URO, 18(2), 2000, pp. 143-147
Authors:
Patel, BJ
Pantuck, AJ
Zisman, A
Tsui, KH
Paik, SH
Caliliw, R
Sheriff, S
Wu, L
deKernion, JB
Tso, CL
Belldegrun, AS
Citation: Bj. Patel et al., CL1-GFP: An androgen independent metastatic tumor model for prostate cancer, J UROL, 164(4), 2000, pp. 1420-1425
Authors:
Gitlitz, BJ
Belldegrun, AS
Figlin, RA
Citation: Bj. Gitlitz et al., Adoptive immunotherapy in renal cell carcinoma, CUR CLIN ON, 4, 2000, pp. 359-379
Authors:
Figlin, RA
Thompson, JA
Bukowski, RM
Vogelzang, NJ
Novick, AC
Lange, P
Steinberg, GD
Belldegrun, AS
Citation: Ra. Figlin et al., Multicenter, randomized, phase III trial of CD8(+) tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma, J CL ONCOL, 17(8), 1999, pp. 2521-2529
Authors:
Palapattu, GS
Naitoh, J
Belldegrun, AS
Citation: Gs. Palapattu et al., Gene therapy for prostate cancer - New perspectives on an old problem, UROL CLIN N, 26(2), 1999, pp. 353
Risultati:
1-16
|